Author's posts
12 States Promised To Open the Books on Their Opioid Settlement Funds. We Checked Up on Them.
Victims of the opioid crisis, health advocates, and public policy experts have repeatedly called on state and local governments to transparently report how they’re using the funds they are receiving from settlements with opioid makers and distributors.
Supreme Court Upends Purdue Pharma Opioid Settlement
The court struck down a $6 billion bankruptcy plan from Purdue Pharma, the maker of OxyContin. What does this mean? We’ll explain.
Swap Funds or Add Services? Use of Opioid Settlement Cash Sparks Strong Disagreements
The national opioid settlements don’t prohibit using money for initiatives already supported by other means, but doing so could dilute the impact.
Statistical Models vs. Front-Line Workers: Who Knows Best How to Spend Opioid Settlement Cash?
A mathematical model designed to direct spending of opioid settlement funds is at the center of a debate over whether to invest in technology to guide long-term decisions or focus on the immediate needs of people in addiction.
Federal Lawmakers Take First Steps Toward Oversight of $50 Billion in Opioid Settlements
The four-page bill lists how states should spend settlement money, but it doesn’t specify consequences for flouting the rules or name who is in charge of monitoring compliance.
In 2023, opioid settlement funds started being paid out. Here’s how it’s going
Some $1.5 billion flowed to local government coffers this year, sparking debates about transparency and how to spend the money. Here are 5 takeaways from a year’s worth of reporting on the issue.
The Year in Opioid Settlements: 5 Things You Need to Know
In the past year, opioid settlement money has gone from an emerging funding stream for which people had lofty but uncertain aspirations to a coveted pot of billions being invested in remediation efforts. Here are some important and evolving factors to watch going forward.
‘They See a Cash Cow’: Corporations Could Consume $50 Billion of Opioid Settlements
As opioid settlement dollars land in government coffers, a swarm of businesses are positioning themselves to profit from the windfall. But will their potential gains come at the expense of the settlements’ intended purpose — to remediate the effects of the opioid epidemic?
Watch and Listen: Opioid Settlement Case Triggers Protests Outside the High Court
The Supreme Court heard arguments over whether the Sacklers, the family behind Purdue Pharma — which marketed OxyContin — could claim immunity from future lawsuits without claiming bankruptcy.
Gubernatorial Candidates Quarrel Over Glory for Winning Opioid Settlements
Some gubernatorial candidates are sparring over bragging rights for their state’s share of $50 billion in opioid settlement funds. Many of the candidates are attorneys general who pursued the lawsuits that produced the payouts.
